Background: Although clozapine is the most effective medication for treatment refractory
schizophrenia, only 40% of people will meet response criteria. We therefore undertook a …

Introduction: Although clozapine (CLZ) is considered the best evidence-based therapeutic
option for treatment of resistant schizophrenia patients, a significant proportion of CLZ …

Objective To integrate all evidence derived from randomized controlled trials (RCTs) of both
pharmacological and nonpharmacological augmentation interventions for clozapine …

Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-
refractory schizophrenia, a substantial proportion of patients receiving clozapine will …

The introduction of antipsychotics in the 1950s revolutionised the treatment of
schizophrenia, but it soon became apparent that a substantial number of patients …

Abstract About 40%-70% of the patients with treatment-resistant schizophrenia have a poor
response to adequate treatment with clozapine. The impact of clozapine-resistant …

Background. When schizophrenia patients have insufficient response to clozapine,
pharmacological augmentation is often applied. This meta-analysis summarizes available …

Objectives: To conduct a meta-analysis of randomized placebo-controlled trials (RCTs) of
clozapine augmentation with another antipsychotic drug in patient with schizophrenia who …

Limited options are available for clozapine-resistant schizophrenia and intolerable side
effects of clozapine. We conducted a systematic review of randomized-controlled trials …

Background Evidence for the management of inadequate clinical response to clozapine in
treatment-resistant schizophrenia is sparse. Accordingly, an international initiative was …